Biotech Growth Trust PLC
Biotech Growth Trust PLC is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Biotech Growth Trust PLC.
Biotech Growth Trust PLC is a company.
Key people at Biotech Growth Trust PLC.
Key people at Biotech Growth Trust PLC.
The Biotech Growth Trust PLC (BIOG) is a UK-listed investment trust that seeks capital appreciation by investing in a diversified portfolio of shares and related securities in biotechnology companies worldwide.[1][2][4] Its mission centers on delivering strong returns through exposure to the global biotech sector, with a philosophy emphasizing active management, high portfolio turnover (170.1% annually), and significant active share (82.2%) relative to its benchmark, the NASDAQ Biotechnology Index.[4] Key sectors are exclusively healthcare/biotechnology (100% allocation), focusing on innovative companies across market caps, including top holdings like Vertex Pharmaceuticals (9.97%), argenx SE (4.75%), and CG Oncology (4.37%).[1][4] With net assets of £293.4m and moderate gearing (6.8% AIC basis), it supports the startup ecosystem by providing liquidity and capital to early- and growth-stage biotech firms, aiding their development of novel therapies.[2][4]
Incorporated on 20 May 1997 as Reabourne Merlin Life Sciences Investment Trust PLC, the trust has evolved through name changes reflecting its sharpening focus on biotechnology: to Finsbury Life Sciences Investment Trust PLC in 1999, Finsbury Emerging Biotechnology Trust PLC in 2005, and its current name in 2007.[3] Managed by Frostrow Capital LLP and co-managed by OrbiMed Capital LLC, a specialist healthcare investor, it shifted from broader life sciences to a pure-play biotech strategy, capitalizing on the sector's growth.[5] This evolution mirrors the biotech boom, with pivotal moments including consistent outperformance tracking and a continuation vote mechanism (next in 2028), underscoring shareholder-driven longevity.[4]
BIOG rides the wave of biotechnology innovation, fueled by advances in gene editing, RNA therapeutics, and precision medicine—evident in holdings like Alnylam (RNAi) and Avidity Biosciences.[1] Timing aligns with post-pandemic R&D surges and aging populations driving demand for novel treatments, with market forces like regulatory tailwinds (e.g., FDA approvals) and M&A activity favoring smaller caps.[4] It influences the ecosystem by channeling public market capital to high-risk biotech startups, bridging venture funding gaps and enhancing sector liquidity on global exchanges.[2][6]
BIOG is poised for growth amid biotech's rebound, with trends like AI-driven drug discovery and oncology breakthroughs likely boosting its diversified portfolio.[4] Expect continued high turnover to capture winners, potential narrowing of its NAV discount via buybacks, and a 2028 continuation vote as a checkpoint. As biotech matures, its influence could expand through larger AUM (£293m+), reinforcing its role in funding the next wave of therapeutic breakthroughs—echoing its origin as a dedicated growth engine in a high-stakes sector.[2][4]
